Melanotan II (MT-II): The Cyclic Melanocortin Agonist Reshaping Pigmentation and Receptor Signaling Research

Introduction: From α-MSH to a Superpotent Cyclic Analog

Researchers can use our peptide comparison page to evaluate pricing and sourcing options.

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that has become one of the most extensively studied melanocortin receptor agonists in modern peptide research. Developed in the early 1990s at the University of Arizona by Victor Hruby, Mac Hadley, and colleagues, MT-II was designed to overcome the inherent limitations of native α-MSH — namely its rapid enzymatic degradation and short biological half-life — while preserving and enhancing melanotropic activity (Hadley & Dorr, 2006).

For dosing, reconstitution, and protocol details, see our Melanotan I (Afamelanotide) Dosage Protocol Guide: MC1R Agonist Research, Reconstitution & Photoprotection 2026 and Melanotan II (MT-II) Dosage Protocol Guide: Reconstitution, Tanning & Melanocortin Research (2026).

The result was a molecule with superpotent melanotropic activity in vitro, exhibiting binding affinity and functional potency at multiple melanocortin receptor (MCR) subtypes that far exceeds the native tridecapeptide α-MSH (Dorr et al., 1996). As a non-selective agonist at MC1R, MC3R, MC4R, and MC5R, MT-II has proven to be an extraordinarily versatile research tool — a molecular probe that has illuminated melanocortin receptor pharmacology, intracellular signaling cascades, and the surprisingly broad physiological roles of this receptor family.

This article examines the structural chemistry, receptor pharmacology, signaling mechanisms, and diverse research applications of Melanotan II. All discussion pertains exclusively to laboratory and in vitro research contexts — MT-II is a research compound intended for investigational use only.

---

Chemical Structure and Design Rationale

Molecular Identity

MT-II bears the systematic sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂, where the bracket notation indicates the lactam bridge that cyclizes the peptide backbone.

Engineering the Core Pharmacophore

The design of MT-II represents a masterclass in rational peptide engineering. The native α-MSH tridecapeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) contains a conserved core pharmacophore at positions 6–9 (His-Phe-Arg-Trp) that is essential for melanocortin receptor binding. Hruby and colleagues applied three key structural modifications to this core:

1. Norleucine substitution (Nle⁴): Methionine at position 4 of α-MSH is susceptible to oxidative degradation. Replacing it with norleucine (Nle) eliminates the thioether group, dramatically improving oxidative stability while maintaining — and in some assays enhancing — receptor binding affinity.

2. D-Phenylalanine incorporation (D-Phe⁷): Inverting the stereochemistry of phenylalanine at position 7 from the L- to D-configuration was a critical modification. This substitution constrains the peptide backbone into a β-turn conformation that optimally presents the His-Phe-Arg-Trp pharmacophore to melanocortin receptor binding pockets. The D-amino acid also confers resistance to enzymatic degradation by endopeptidases.

3. Lactam bridge cyclization (Asp⁵-Lys¹⁰): The defining structural feature of MT-II is the intramolecular lactam bridge formed between the side-chain carboxyl group of aspartic acid (position 5) and the ε-amino group of lysine (position 10). This covalent macrocyclization constrains the peptide into a rigid, bioactive conformation that reduces the entropic penalty of receptor binding and dramatically enhances both potency and metabolic stability (Lan et al., 1994).

Together, these modifications transform a labile, low-potency linear tridecapeptide into a compact, enzymatically resistant cyclic heptapeptide with superpotent activity across multiple melanocortin receptor subtypes.

---

The Melanocortin Receptor System: MT-II's Molecular Targets

Understanding MT-II's research utility requires familiarity with the melanocortin receptor (MCR) family — five Class A G-protein coupled receptors (GPCRs) designated MC1R through MC5R. Each subtype has distinct tissue distribution patterns and physiological roles (Cai et al., 2016):

MC1R — Pigmentation and Inflammation

MC1R is predominantly expressed on melanocytes and immune cells (macrophages, monocytes, neutrophils). On melanocytes, MC1R activation drives eumelanin synthesis through the cAMP/PKA/MITF/tyrosinase signaling cascade. On immune cells, MC1R activation suppresses NF-κB signaling and pro-inflammatory cytokine release. MT-II binds MC1R with high affinity, making it a primary tool for pigmentation research in melanocyte culture systems.

MC3R — Energy Homeostasis and Immune Modulation

MC3R is expressed in the hypothalamus (particularly the arcuate nucleus), peripheral tissues, and macrophages. It plays roles in energy homeostasis, nutrient partitioning, and inflammatory regulation. Studies have demonstrated that MT-II activates MC3R on peritoneal macrophages to inhibit experimental inflammatory responses in vitro (Getting et al., 2001).

MC4R — Central Energy Regulation

MC4R is the predominant melanocortin receptor in the central nervous system, expressed throughout the hypothalamus, brainstem, and cortex. It is a master regulator of energy balance, with MC4R mutations representing the most common monogenic cause of obesity in research models. MT-II's agonism at MC4R has made it an indispensable tool in studying feeding behavior circuits, energy expenditure regulation, and hypothalamic signaling in laboratory settings (Tao, 2010).

MC5R — Exocrine Function

MC5R is expressed in sebaceous glands, adrenal glands, and various peripheral tissues. It participates in exocrine gland regulation and lipid metabolism. MT-II's activity at MC5R has enabled investigations into sebaceous lipogenesis and exocrine secretory pathways in cell culture models.

MC2R — The Exception

Notably, MT-II does not bind MC2R (the ACTH receptor), which is exclusive to the adrenal cortex and requires the accessory protein MRAP for surface expression. This selectivity profile — active at MC1R/MC3R/MC4R/MC5R but inactive at MC2R — is a defining pharmacological characteristic of the compound.

---

Signal Transduction: How MT-II Activates Intracellular Cascades

The Canonical cAMP/PKA Pathway

All melanocortin receptors primarily couple to Gαs proteins. When MT-II binds to an MCR subtype, the activated receptor catalyzes GDP-to-GTP exchange on the Gαs subunit, which then stimulates adenylyl cyclase. The resulting elevation in intracellular cyclic AMP (cAMP) activates protein kinase A (PKA), which phosphorylates downstream effectors including:

• •CREB (cAMP Response Element-Binding protein): Transcription factor that drives expression of melanogenic enzymes (tyrosinase, TRP-1, TRP-2) via MITF upregulation in melanocyte systems
• •HSL (Hormone-Sensitive Lipase): Relevant in adipocyte research models studying lipolysis
• •Ion channels: PKA-dependent phosphorylation of various channel proteins affects neuronal excitability in hypothalamic slice preparations

Non-Canonical Signaling: MAPK and Beyond

Beyond the classical Gαs/cAMP pathway, MT-II engagement of MC4R has been shown to activate MAPK (mitogen-activated protein kinase) signaling cascades, including ERK1/2 phosphorylation, in both cell culture and tissue preparations. This has significant implications for research into melanocortin-dependent gene expression programs that are cAMP-independent.

MT-II also exhibits functional selectivity (biased agonism) at certain receptor subtypes — meaning it can preferentially activate specific downstream pathways depending on the receptor context. Recent work using CLIPS (Chemical Linkage of Peptides onto Scaffolds) technology has generated MT-II-derived analogs with varying degrees of functional selectivity across MCR subtypes, highlighting the compound's value as a scaffold for developing pathway-selective probes (Tomassi et al., 2022).

Receptor Desensitization and Internalization

In cell-based assay systems, sustained MT-II exposure leads to MCR phosphorylation by GRKs (G-protein-coupled receptor kinases), recruitment of β-arrestins, and clathrin-mediated receptor internalization. This desensitization mechanism is an important consideration in experimental design, as it affects the temporal dynamics of signaling responses in prolonged in vitro exposure protocols.

---

Research Applications of Melanotan II

Melanogenesis and Pigmentation Biology

MT-II's most established research application is in melanocyte biology. In primary melanocyte cultures and melanoma cell lines (e.g., B16 murine melanoma), MT-II potently stimulates:

• •Eumelanin synthesis via MC1R-dependent upregulation of the tyrosinase enzyme family
• •Melanocyte dendricity — the extension of cellular processes that facilitate melanin transfer to neighboring keratinocytes in co-culture models
• •MITF (Microphthalmia-associated Transcription Factor) expression — the master transcriptional regulator of melanocyte differentiation and survival

These properties have made MT-II a standard positive control in melanogenesis assays and a valuable tool for studying UV-independent melanin production pathways. The compound's early development was specifically motivated by investigating whether enhanced melanization could serve as a photoprotective strategy against UV-induced DNA damage in skin cell models (Lan et al., 1994).

Energy Homeostasis and Metabolic Signaling

MT-II has been instrumental in elucidating the central melanocortin system's role in energy balance regulation. In hypothalamic neuronal culture systems and brain slice preparations, MT-II studies have revealed:

• •MC4R-dependent anorexigenic signaling: MT-II activation of hypothalamic MC4R neurons modulates firing rates and neuropeptide release in electrophysiology preparations
• •Interaction with NPY/AgRP circuits: In dual-perfusion models, MT-II has been shown to counteract NPY-induced orexigenic signaling through MC3R/MC4R activation, demonstrating the antagonistic interplay between these hypothalamic circuits (Raposinho et al., 2003)
• •Thermogenic signaling: MT-II activates sympathetic outflow pathways in brainstem preparations, providing insights into melanocortin-dependent energy expenditure regulation

Inflammatory and Immune Modulation Research

The melanocortin system has emerged as a significant immunomodulatory axis, and MT-II has been central to these discoveries:

• •Macrophage functional modulation: MT-II activates MC3R on macrophages to suppress pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) and reduce chemokine release (KC/CXCL1) in culture systems (Getting et al., 2003)
• •NF-κB pathway suppression: MT-II-mediated MCR activation has been shown to inhibit NF-κB nuclear translocation in various immune cell types in vitro
• •Resolution of inflammation: MC3R activation by MT-II promotes pro-resolving mediator release, suggesting a role in active inflammation resolution pathways

Neuroprotection and Neural Signaling

The wide distribution of MC3R and MC4R in the central nervous system has driven extensive neuroprotection research with melanocortin agonists including MT-II (Catania, 2008). In neural cell cultures and organotypic brain slice models, MT-II has been studied in the context of:

• •Oxidative stress models: MT-II exposure has been associated with reduced markers of oxidative damage in neuronal culture systems challenged with hydrogen peroxide or other ROS generators
• •Neuroinflammatory signaling: Through microglial MC3R/MC4R activation, MT-II modulates the M1/M2 polarization balance in primary microglial cultures
• •Synaptic plasticity: MT-II influences long-term potentiation (LTP) parameters in hippocampal slice preparations, suggesting melanocortin involvement in synaptic strength regulation

---

MT-II as a Scaffold: Derivatives and Next-Generation Analogs

One of MT-II's most significant contributions to peptide science is its role as a structural scaffold for developing receptor-selective melanocortin agonists and antagonists. Key derivatives include:

PT-141 (Bremelanotide)

PT-141 is the active metabolite of MT-II, formed by removal of the N-terminal acetyl-norleucine residue. This structural modification shifts the pharmacological profile toward preferential MC3R/MC4R activity. PT-141's development trajectory — from an MT-II metabolite to an independently characterized research compound — illustrates how studying one peptide can generate entirely new molecular entities for investigation (King et al., 2003). Researchers can use our dose plotter to visualize dose-response curves across melanocortin receptor agonists.

Afamelanotide (Melanotan I / NDP-MSH)

While not a direct MT-II derivative, afamelanotide (Nle⁴-D-Phe⁷-α-MSH) is a linear analog that shares MT-II's key Nle⁴ and D-Phe⁷ substitutions without the lactam cyclization. Comparing MT-II with afamelanotide in receptor binding assays has been valuable for understanding how macrocyclization affects receptor selectivity, binding kinetics, and signaling bias.

CLIPS-Derived Analogs

Recent work has used Chemical Linkage of Peptides onto Scaffolds (CLIPS) technology to generate constrained MT-II analogs with novel receptor selectivity profiles. By modifying the cyclization chemistry while preserving the core pharmacophore, researchers have created compounds with functional selectivity at individual MCR subtypes — tools that are unavailable from the parent MT-II molecule alone (Tomassi et al., 2022).

SHU-9119: The Antagonist Counterpart

SHU-9119 is a close structural analog of MT-II in which D-Phe⁷ is replaced with D-Nal(2')⁷ (D-2-naphthylalanine). This single substitution converts the compound from an MC3R/MC4R agonist to an MC3R/MC4R antagonist while retaining MC1R/MC5R agonist activity. The MT-II / SHU-9119 pair has been invaluable for dissecting receptor-specific contributions to observed biological effects in mixed receptor expression systems.

---

Stability, Handling, and Analytical Considerations

Physicochemical Stability

MT-II's cyclic structure confers substantially greater stability compared to linear melanocortin peptides:

• •Enzymatic resistance: The lactam bridge and D-Phe⁷ substitution protect against endopeptidase and exopeptidase degradation, extending stability in biological matrices (serum, tissue homogenates)
• •Thermal stability: Lyophilized MT-II is stable for extended periods at -20°C. In solution, the peptide maintains integrity at 4°C for days to weeks depending on buffer composition and pH
• •pH sensitivity: Preformulation studies have characterized dissociation constants at pKa₁ = 6.54 (His imidazole) and pKa₂ = 11.72 (Arg guanidinium), with optimal stability in the pH 4–6 range (Lan et al., 1994)
• •Oxidative vulnerability: Despite the Nle⁴ substitution eliminating methionine oxidation, the tryptophan residue (Trp⁹) remains susceptible to oxidative degradation. Storage under inert gas (nitrogen or argon) is recommended for long-term stability

Reconstitution Best Practices for Research

For laboratory use, MT-II is typically reconstituted in bacteriostatic water or sterile saline. Use our reconstitution calculator for precise mixing ratios. Due to the peptide's moderate hydrophobicity (conferred by the Nle, D-Phe, and Trp residues), brief sonication or gentle vortexing may be required to achieve complete dissolution at higher concentrations. Researchers should consult our Peptide Solubility and Solvent Selection Guide and How to Reconstitute Peptides for detailed protocols.

Quality Assessment

When evaluating MT-II for research use, critical quality parameters include:

• •Purity by RP-HPLC: Research-grade MT-II should exhibit ≥98% purity on C18 reverse-phase HPLC
• •Mass confirmation by ESI-MS: The expected [M+H]⁺ ion at m/z 1024.5 should be confirmed by electrospray ionization mass spectrometry
• •Peptide content: Net peptide content (excluding counterions and adsorbed moisture) is typically 70–85% for acetate salt forms
• •Residual solvent analysis: Particularly important for lyophilized preparations from SPPS manufacturing

For a deeper understanding of these analytical methods, see our guides on Peptide Purity Testing Methods: HPLC and Mass Spectrometry Explained and How to Read a Certificate of Analysis.

---

Relationship to Other Research Peptides

MT-II occupies a unique position in the melanocortin peptide landscape. Understanding its relationship to related compounds helps researchers select the appropriate tool for specific experimental questions:

• •vs. α-MSH: MT-II is more potent, longer-lasting, and enzymatically resistant, but non-selective across MC1R/3R/4R/5R whereas α-MSH has modest MC1R preference
• •vs. PT-141 (Bremelanotide): PT-141 is an MT-II metabolite with shifted selectivity toward MC3R/MC4R. Researchers studying pigmentation pathways may prefer MT-II; those focused on central melanocortin signaling may choose PT-141
• •vs. NDP-MSH (Afamelanotide): Linear vs. cyclic comparison — afamelanotide retains the Nle⁴ and D-Phe⁷ modifications but lacks the constraining lactam bridge, resulting in different conformational dynamics and receptor interaction kinetics
• •vs. KPV: KPV is the C-terminal tripeptide of α-MSH (Lys-Pro-Val) with anti-inflammatory properties that appear to be largely MCR-independent, offering a contrasting mechanism to MT-II's receptor-mediated effects
• •vs. SHU-9119: Structural near-twin of MT-II that functions as an MC3R/MC4R antagonist — the pair is essential for pharmacological dissection experiments

---

Current Research Frontiers

Biased Agonism and Functional Selectivity

One of the most active areas of MT-II research involves understanding how the same ligand can activate different signaling cascades at the same receptor depending on cellular context. MT-II has been shown to exhibit varying degrees of bias between Gαs/cAMP and β-arrestin recruitment pathways across MCR subtypes, making it a model compound for studying GPCR signaling complexity.

Structure-Activity Relationships (SAR)

MT-II continues to serve as the primary scaffold for melanocortin SAR studies. Systematic modification of individual residues, cyclization chemistry, and stereochemistry has generated hundreds of analogs with diverse selectivity profiles. This ongoing work aims to develop truly subtype-selective MCR agonists and antagonists — a goal that remains challenging given the high sequence homology among MCR binding pockets.

Combinatorial Applications

Researchers are exploring MT-II in combination with other signaling modulators in cell-based assay systems. For example, co-application of MT-II with GHK-Cu in skin cell models, or alongside neuroprotective peptides such as Semax in neural culture systems, allows investigation of synergistic or antagonistic pathway interactions.

---

Conclusion

Melanotan II stands as one of the most consequential synthetic peptides in melanocortin research. Its rational design — combining norleucine substitution, D-amino acid incorporation, and lactam macrocyclization — created a superpotent, enzymatically resistant, non-selective MCR agonist that has served as both a direct research tool and a structural scaffold for next-generation analogs.

From illuminating the cAMP/PKA/MITF signaling cascade in melanocyte biology to dissecting hypothalamic energy homeostasis circuits, from probing melanocortin-dependent immunomodulation to enabling the discovery of functionally selective MCR ligands, MT-II has proven indispensable to multiple domains of biomedical investigation.

As research continues to reveal new facets of melanocortin receptor pharmacology — including biased signaling, allosteric modulation, and receptor heteromerization — MT-II will undoubtedly remain a cornerstone compound in the peptide researcher's toolkit.

---

References

• •PMID: 41752902
• •PMID: 39442746
• •PMID: 39302005

1. Dorr, R.T., et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777-1784. PubMed

2. Lan, E.L., et al. (1994). Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. Journal of Pharmaceutical Sciences, 83(8), 1081-1084. PubMed

3. Hadley, M.E., & Dorr, R.T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921-930. PubMed

4. Cai, M., & Hruby, V.J. (2016). The melanocortin receptor system: a target for multiple degenerative diseases. Current Protein and Peptide Science, 17(5), 488-496. PubMed

5. Getting, S.J., et al. (2001). Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. Journal of Leukocyte Biology, 69(1), 98-104. PubMed

6. Getting, S.J., et al. (2003). MC3-R as a novel target for antiinflammatory therapy. Drug News & Perspectives, 16(6), 405-411. PubMed

7. Catania, A. (2008). Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends in Neurosciences, 31(7), 353-360. PubMed

8. Raposinho, P.D., et al. (2003). The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y. European Journal of Endocrinology, 148(2), 241-250. PubMed

9. Tomassi, S., et al. (2022). CLIPSing Melanotan-II to discover multiple functionally selective hMCR agonists. Journal of Medicinal Chemistry, 65(5), 4007-4017. PubMed

10. King, S.H., et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Current Topics in Medicinal Chemistry, 3(8), 845-853. PubMed

11. Tao, Y.X. (2010). Effect of MTII on food intake and brain c-Fos in melanocortin-3, melanocortin-4, and double MC3 and MC4 receptor knockout mice. Peptides, 31(12), 2314-2317. PubMed

---

Further Reading:

• •PT-141 (Bremelanotide): Melanocortin Receptor Agonist Research Profile
• •Galanin: The Pleiotropic Neuropeptide Bridging Neuroscience, Metabolic, Pain, and Oncology Research
• •CGRP (Calcitonin Gene-Related Peptide): The Vasodilatory Neuropeptide Bridging Pain, Cardiovascular, and Tissue Repair Research
• •PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide): The Pleiotropic Neuropeptide Driving Neuroscience and Stress Research
• •Reconstitution Calculator
• •Peptide Stack Builder

---

Disclaimer: This article is intended for educational and research purposes only. Melanotan II is a research compound sold exclusively for laboratory investigation. It is not approved for human or animal use and should not be employed outside of properly supervised research settings. All references to biological activity describe findings from in vitro, cell culture, or controlled laboratory studies.

---

Melanotan II: Live Supplier Pricing (2026)

Research-grade Melanotan II pricing from the Peptides.SO listings database.

Prices from Peptides.SO database. Verify current pricing before purchase. MT-II is a research compound — EU sale restricted in several jurisdictions. For laboratory use only.

Regulatory note: MT-II is banned for cosmetic sale in the UK, EU, and several other jurisdictions. Research-grade procurement for laboratory investigation operates under different regulatory frameworks. Verify your local regulations.

For live pricing, use the peptide comparison tool or /peptide/melanotan-2.

---

Frequently Asked Questions About Melanotan II Research

Q: How does Melanotan II's cyclic structure affect its receptor binding and metabolic stability versus linear melanocortin peptides?

A: MT-II's lactam bridge (connecting Asp5-Lys10) creates a constrained conformation that locks the pharmacophore region (His-Phe-Arg-Trp) into a high-affinity binding orientation across multiple melanocortin receptors. This cyclic constraint provides three key research advantages: (1) increased receptor affinity vs. linear α-MSH (MT-II Ki at MC4R ~0.3 nM vs. α-MSH ~6 nM), (2) resistance to exopeptidase degradation that would cleave the N-terminus of linear peptides, and (3) extended half-life in biological fluids (~1 hour vs. minutes for native α-MSH).

Q: What distinguishes MT-II's mechanism of sexual function effects from pharmacological comparators?

A: MT-II activates MC4R in the paraventricular nucleus and spinal cord circuits, triggering non-nitric oxide-dependent signaling cascades that promote penile erection in rodent models. This mechanistic distinction from PDE5 inhibitors (sildenafil, tadalafil — which require sexual stimulation and act downstream on NO/cGMP) positions MT-II research in a different pharmacological niche: central (rather than peripheral) pro-erectile mechanism. This eventually led to PT-141 (bremelanotide), a structurally related compound that received FDA approval as Vyleesi for HSDD.

Q: What preclinical evidence supports MT-II's anorexigenic effects and how does this compare to GLP-1 agonists?

A: MT-II's appetite suppression is mediated through MC4R in the hypothalamus — specifically the arcuate nucleus (ARC) POMC/AgRP neuron circuit. This mechanism is upstream and independent of the GLP-1R pathway used by semaglutide and tirzepatide. In rodent models, MT-II produces acute anorexia with dose-dependent food intake reduction that is fully blocked by MC4R antagonists. GLP-1R agonists act through a parallel but distinct hypothalamic circuit (also in ARC but via different second-messenger pathways). The two mechanisms have been combined in research models to study additive appetite suppression.

Q: What are the key nausea-induction mechanisms that make MT-II problematic in research subjects?

A: MT-II-induced nausea in research subjects is mediated through MC4R in the area postrema (the "vomiting center" in the brainstem) and MC3R in the gut. The area postrema lacks a blood-brain barrier, making it accessible to peripherally administered peptides. This same MC4R/area postrema mechanism is why semaglutide and other GLP-1R agonists — which also activate area postrema circuits — cause nausea. MT-II's additional MC3R activity amplifies the emetic signal. This nausea mechanism has been a barrier to MT-II clinical development outside of specific contexts.

Q: How does MT-II's regulatory status affect research procurement in different jurisdictions?

A: MT-II's regulatory status varies by country. In the UK and EU, MT-II is banned for cosmetic sale and is not licensed for any indication. In the US, MT-II is not FDA-approved but is not explicitly scheduled — research-grade procurement for laboratory use is legal with appropriate RUO documentation. In Canada, MT-II requires researcher authorization under Part C of the Food and Drugs Regulations. Researchers should verify current regulatory status in their jurisdiction before procurement.

Q: What documentation should researchers verify before purchasing MT-II for laboratory use?

A: Minimum documentation: (1) Certificate of Analysis (COA) with HPLC purity ≥95% and mass spectrometry identity confirmation — MT-II's molecular weight is 1024.2 Da, verify [M+H]+ = 1025.2 or [M+2H]2+ = 513.1; (2) Research Use Only (RUO) labeling on product; (3) supplier's COA from accredited third-party laboratory. See how to read a peptide COA for complete verification guide.

---

Disclaimer: This article is intended for educational and research purposes only. Melanotan II is a research compound sold exclusively for laboratory investigation. It is not approved for human or animal use. Sale for cosmetic tanning purposes is banned in the UK, EU, and other jurisdictions. Researchers must comply with all applicable regulations in their jurisdiction.

Research Supplier Comparison: Melanotan II (MT-II) Pricing (August 2026)

Melanotan II is among the most price-competitive research melanocortin compounds on the platform. Peptides.SO tracks 40+ suppliers carrying MT-II across 60+ active listings. Pricing is expressed per mg of lyophilized peptide.

Pricing context: MT-II is typically sold in 10mg vials. At $2–8/mg, a 10mg research vial runs $20–$80 — making MT-II relatively affordable compared to GLP-1 compounds or larger peptides. For full live pricing including all supplier discount codes, see the Melanotan II comparison page.

> For research use only. MT-II is a research peptide not approved for human therapeutic use. Sale for cosmetic tanning is banned in the UK, EU, and other jurisdictions. Researchers must verify regulatory status in their jurisdiction before procurement.

---

Frequently Asked Questions: Melanotan II Research

Q: What is Melanotan II and how does it relate to the endogenous melanocortin system?

A: Melanotan II (MT-II) is a cyclic heptapeptide analog of α-melanocyte stimulating hormone (α-MSH), itself a fragment of pro-opiomelanocortin (POMC). Its cyclic structure — created through a lactam bridge between Asp and Lys residues — provides substantially greater receptor potency and plasma half-life than the linear parent α-MSH sequence. MT-II is a non-selective melanocortin receptor agonist, activating MC1R (pigmentation), MC3R (energy metabolism), MC4R (appetite suppression, sexual function), and MC5R (exocrine glands) with varying affinities. This broad receptor profile makes MT-II a useful pharmacological tool for studying melanocortin receptor biology across multiple physiological systems simultaneously, though it also produces a complex multi-system pharmacological signature that researchers must account for in experimental design.

Q: What are the key purity standards researchers should require for MT-II procurement?

A: MT-II has a molecular weight of 1024.2 Da; mass spectrometry identity confirmation should show [M+H]⁺ = 1025.2 or the doubly-charged ion [M+2H]²⁺ = 513.1 as the dominant species. HPLC purity ≥98% (99% preferred for mechanistic studies) is the accepted standard. The cyclic structure means that correct MS identity is particularly important — a linear (non-cyclized) synthetic contaminant would have the same sequence and similar mass but substantially different pharmacological activity. Request disulfide bridge or lactam bridge confirmation documentation where available. Third-party independent laboratory testing (Janoshik, Colmaric, US-based academic labs) provides stronger QC confidence than supplier-generated COAs alone. See How to Read a Peptide COA for complete evaluation guidance.

Q: How does MT-II compare to Afamelanotide (Scenesse) in melanocortin research?

A: Afamelanotide (Scenesse; NDP-α-MSH) is an FDA-approved melanocortin agonist for erythropoietic protoporphyria (EPP) and the closest clinically validated melanocortin tool to MT-II. Both are α-MSH analogs, but afamelanotide uses a D-Phe substitution at position 7 (rather than MT-II's cyclic lactam constraint) to achieve receptor stability. MT-II has broader MC receptor activity (hitting MC4R more strongly), while afamelanotide is somewhat more MC1R-selective. For pigmentation pathway research, afamelanotide provides a clinically-characterized reference standard; for MC4R-mediated appetite/sexual function research, MT-II is the more established preclinical tool given its stronger MC4R engagement and the extensive published literature using it as the receptor agonist.

---

Safety Profile and Preclinical Risk Assessment

> Research Use Only Disclaimer: Melanotan II is not approved by the FDA or any major regulatory authority for human therapeutic use. The following section summarizes safety data from controlled preclinical studies and early-phase human pharmacology research (Phase I/II) published in peer-reviewed literature. This information is provided for research context only and does not constitute medical advice or treatment guidance.

The safety profile of Melanotan II has been characterized primarily through controlled clinical trials targeting its initial primary indication — erection-generating activity — and through surveillance of uncontrolled human use documented in pharmacovigilance literature. Across this body of evidence, several consistent adverse effect patterns emerge alongside significant gaps in long-term safety data.

Established Adverse Effects from Controlled Human Pharmacology Studies

Nausea and Gastrointestinal Effects

Spontaneous Penile Erections

Cardiovascular and Hemodynamic Effects

MT-II administration produces transient hemodynamic changes including modest increases in systolic blood pressure (typically 5–15 mmHg above baseline) and heart rate elevations, mediated through central MC4R activation and peripheral vascular tone modulation. These effects are generally mild and self-limiting, but represent a meaningful consideration in subjects with pre-existing cardiovascular conditions. No serious cardiac adverse events were reported in controlled Phase I studies.

Facial Flushing and Thermoregulatory Effects

Facial flushing (erythema), yawning, and mild fatigue have been reported across multiple controlled trials, consistent with central melanocortin receptor activation affecting autonomic and thermoregulatory circuits.

Dermatological and Melanogenesis Concerns

The oncological significance of melanocyte stimulation in the context of existing dysplastic nevi or familial melanoma risk remains a major unresolved safety question. While no controlled studies have established a causal link between MT-II use and melanoma development, the theoretical risk — given that MT-II directly activates MC1R and MC4R in melanocytes and promotes eumelanin production — warrants serious consideration in any research protocol design.

Pharmacovigilance Evidence

Long-Term Safety Data Gaps

A critical limitation in the MT-II safety literature is the near-complete absence of long-term safety data from controlled human studies. Development of MT-II for human therapeutic use was discontinued after early Phase II data in favor of more selective melanocortin receptor analogs (afamelanotide for erythropoietic protoporphyria; bremelanotide/PT-141 for hypoactive sexual desire disorder). Consequently:

• •No controlled data exist beyond 6-month follow-up timeframes
• •Carcinogenicity has not been systematically evaluated in long-duration human exposure studies
• •Reproductive and developmental toxicity data in humans are absent
• •Drug-drug interaction studies were not conducted beyond early Phase I assessments

Animal Toxicology Summary

In rodent models, MT-II administration at pharmacological doses did not produce acute toxicity signals in short-term studies. Melanocyte stimulation in animal models has been studied primarily in the context of melanoma xenograft models (where MC1R activation effects on tumor progression were investigated) rather than for MT-II-specific toxicological characterization.

Practical Safety Considerations for Research Use

For researchers working with MT-II in preclinical or early-phase contexts, the following considerations arise from the available evidence:

All research protocols involving Melanotan II should include appropriate dermatological monitoring, cardiovascular screening, and institutional review board oversight consistent with the regulatory status of unapproved investigational compounds.

References — Safety Data

• •Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. PMID: 16412534